In this research the clinical benefits of crizotinib in patients with brain metastases have been studied. Crizotinib was associated with systemic and intracranial disease control in patients with ALK-rearranged NSCLC who were ALK inhibitor naive and had brain metastases.

READ FULL ARTICLE Curated publisher From Mdlinx